Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immune-Activated B Cells Are Dominant in Prostate Cancer. | Cancers (Basel) | 2023 | 36765877 | PubTator, text mining | PubMed |
| Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution. | Cancers (Basel) | 2023 | 36765855 | PubTator, text mining | PubMed |
An Optimized Single Nucleotide Polymorphism-Based Detection Method Suggests That Allelic Variants in the 3' Untranslated Region of RRAS2 Correlate with Treatment Response in Chronic Lymphocytic Leukemia Patients. | Cancers (Basel) | 2023 | 36765602 | PubTator, text mining | PubMed |
| A systematic review evaluating the efficacy of autologous hematopoietic transplantation for diffuse large B cell lymphoma-type Richter syndrome. | Caspian J Intern Med | 2023 | 36741500 | PubTator, text mining | PubMed |
| Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma. | Ann Hematol | 2023 | 36735075 | PubTator, text mining | PubMed |
| Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors. | Blood Cancer J | 2023 | 36732326 | PubTator, text mining | PubMed |
| Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia. | Exp Hematol Oncol | 2023 | 36707896 | PubTator, text mining | PubMed |
| DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease. | Blood Cancer J | 2023 | 36707503 | PubTator, text mining | PubMed |
| Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients. | Indian J Hematol Blood Transfus | 2023 | 36699426 | PubTator, text mining | PubMed |
| Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. | Blood Adv | 2023 | 36689726 | PubTator, text mining | PubMed |
| Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review. | Pharmaceutics | 2023 | 36678867 | PubTator, text mining | PubMed |
| Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia. | Int J Mol Sci | 2023 | 36675221 | PubTator, text mining | PubMed |
| Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study. | Cancers (Basel) | 2023 | 36672456 | PubTator, text mining | PubMed |
| Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. | Nat Commun | 2023 | 36658118 | PubTator, text mining | PubMed |
| The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy. | Haematologica | 2023 | 36655432 | PubTator, text mining | PubMed |
| Infection with Neoehrlichia mikurensis promotes the development of malignant B-cell lymphomas. | Br J Haematol | 2023 | 36650117 | PubTator, text mining | PubMed |
| CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia. | Exp Hematol Oncol | 2023 | 36635772 | PubTator, text mining | PubMed |
| Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. | Leukemia | 2023 | 36635392 | PubTator, text mining | PubMed |
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. | Haematologica | 2023 | 36632738 | PubTator, text mining | PubMed |
| Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination. | Blood Adv | 2023 | 36630562 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=22